Emergent

Article

Sponsored Content

Emergent provides contract manufacturing services for the aseptic fill/finish of vials and syringes: liquid and lyophilized products.

Emergent provides contract manufacturing services for the aseptic fill/finish of vials and syringes: liquid and lyophilized products. Emergent’s manufacturing facility currently produces 20 commercial products and has contributed to the development of over 200 clinical products.

Emergent BioSolutionswww.ebsi.com/CMO
CMO@ebsi.com 
tel. 800.441.4225

Recent Videos
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content
High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

Pushing Tech Boundaries

Mike Hennessy Jr.
March 3rd 2025
Article

Artificial intelligence, among other technological advances, is pushing innovation boundaries.

Drug Solutions Podcast: Forecasting Pharma’s Future

Drug Solutions Podcast: Forecasting Pharma’s Future

Felicity Thomas
January 31st 2025
Podcast

This episode is a compilation of comments taken from a series of interviews where experts reveal the trends that have impacted the bio/pharma industry in 2024 and those they expect to be impactful in 2025.

TOP NEWS on grunge world map | Image Credit: © Sean K - stock.adobe.com

Rare Disease Day Celebrated on February 28

Patrick Lavery
March 1st 2025
Article

More than 6000 rare diseases—those which affect fewer than one in 2000 people each—are acknowledged in the medical community, with 72% of them being genetic.

Drug Solutions Podcast: Realizing AI’s Potential

Drug Solutions Podcast: Realizing AI’s Potential

Felicity Thomas
December 20th 2024
Podcast

This episode is a compilation of comments taken from a series of interviews where experts are discussing how AI might impact the global bio/pharma industry in the future.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

EMA Recommends Four Medicines for Approval in February

Susan Haigney
February 28th 2025
Article

Treatments for autoimmune diseases, multiple cancers, and skin blistering have been recommended for marketing approval.

Site Logo

Executive Summary: Leveraging the Evolving Bioequivalence Regulatory Landscape to Enhance Inhaled Product Design and Development

Vectura Group plc;Vectura
February 28th 2025
Article

The regulatory landscape for bioequivalence continues to evolve, leveraging a broader suite of characterization techniques. These not only provide deeper product understanding, but also utility for generic product development as the potential for replacement of costly clinical studies becomes more of a reality.